Moxonidine for Prevention of Post-ablation AFib Recurrences

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypothesis: Modulation of central nervous sympathetic activation by administration of moxonidine, a centrally acting medication which decreases the sympathetic nervous system activity, can lead to a decrease in atrial fibrillation recurrence after ablation treatment with pulmonary vein isolation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Spyridon Deftereos
• Treatments: Moxonidine

Criteria

Inclusion Criteria:

• Hypertensive patients with paroxysmal atrial fibrillation.

• At least two documented episodes within the last 12 months (either self-terminating within 7 days or cardioverted, medically or electrically, in less than 48 hours).

• At least one episode should have been documented under treatment with a class Ic or III antiarrhythmic drug.

Exclusion Criteria:

1. age <25 or >80 years

2. presence of atrial thrombus

3. left atrial volume index >55 ml/m2

4. hypersensitivity to moxonidine

5. sick sinus syndrome or sino-atrial block

6. 2nd or 3rd degree atrioventricular block

7. bradycardia (below 50 beats/minute at rest)

8. estimated glomerular filtration rate <40 ml/min/1.73 m2

9. history of angioneurotic oedema

10. heart failure symptoms OR impaired left ventricular function (EF <40%), even if asymptomatic

11. stable or unstable angina pectoris

12. intermittent claudication or known peripheral artery disease

13. Parkinson's disease

14. epileptic disorders

15. glaucoma

16. history of depression

17. pregnancy or lactation

18. inability or unwillingness to adhere to standard treatment or to provide consent.